Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-guided sequential triazole therapy following liposomal amphotericin B for invasive fungal disease
ChiCTR2600130801Phase 4Not yet recruiting
- Sponsor
- Tianjin Integrated Traditional Chinese and Western Medicine Hospital
- Start
- Jun 2026
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liposomal amphotericin b and voriconazole in invasive mycoses, sponsored by Tianjin Integrated Traditional Chinese and Western Medicine Hospital. Primary endpoint: Overall 6-week survival rate of all enrolled patients. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
liposomal amphotericin bvoriconazole
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on ChiCTR2600130801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130801.